Healthcare information corporate ConcertAI introduced a multi-year settlement with pharmaceutical and biotechnology large Bayer to make use of ConcertAI’s Translational360 and AI SaaS choices.
The choices use AI- and gadget learning-acquired insights to hurry up medical building in precision oncology.
The settlement targets to make use of ConcertAI’s Translational360 providing, an built-in research-level longitudinal medical molecular database that harnesses the CancerLinQ community of anonymized most cancers affected person information from greater than 9 million data from all 50 states.
Translational360 contains “medical, genomic, transcriptomic and whole-slide imaging from complete molecular trying out for deep phenotypical and genomic insights.”
Transcriptomics permits researchers to grasp illness molecular mechanisms, the foundation of affected person reaction and inter-patient flexibility, which is an important for creating new therapeutics.
Combining built-in information answers and AI will permit for deciding on methods with the easiest chance of good fortune and design trials influenced through multimodal, multi-genomic and transcriptomic information and AI.
“This partnership builds on a multi-year historical past of operating in combination and is exclusive in providing each tissue and liquid biopsy molecular information, permitting insights into patterns of remedy reaction, acquisition of resistance, AI modeling of most likely good fortune and get advantages, informing program precedence and medical find out about design,” Jeff Elton, CEO of ConcertAI, stated in a remark.
THE LARGER TREND
Ultimate yr, ConcertAI named Dhiraj Carumbay as senior vice chairman and common supervisor of the corporate’s TeraRecon industry.
Carumbay controlled industry devices at RadNet, Amazon AWS, Philips Healthcare, Fujifilm and GE HealthCare. At AWS, he oversaw Amazon’s cloud answers for the healthcare and life-sciences industries. Ahead of that, he held industry management and international product roles at GE HealthCare.
In 2023, ConcertAI expanded its partnership with Caris Existence Sciences. The corporations collectively created a database to generate insights to advance precision drugs, medical trial control and healing building.
The companions advanced a database that leveraged each corporations’ medical, molecular and multimodal information to allow teachers and biopharma researchers to realize insights for oncology-focused precision drugs, medical trial control and healing building.
In 2022, ConcertAI scored $150 million in Sequence C investment. The spherical bumped the then-5-year-old corporate’s valuation to $1.9 billion. As a part of the deal, 6th Side road’s managing director, Adam Kaye, joined ConcertAI’s board, and Managing Director Lee Mooney was once named a board observer.
In 2024, GenAI radiology workflow corporate Rad AI and Bayer collaborated to carry Rad AI’s era to the multinational pharmaceutical and biotechnology corporate’s Calantic Virtual Resolution consumers.
Calantic is a vendor-neutral cloud-based market of AI-enabled radiology apps aimed toward automating regimen radiology duties. Rad AI provides radiologists generative AI equipment to assist streamline workflows, together with doctor dictation and follow-up care control choices.
That very same yr, Google Cloud and Bayer partnered to expand AI programs aimed toward decreasing radiologist burnout and extending efficiencies in diagnoses.
Bayer expanded its innovation platform the usage of Google Cloud era, together with its generative AI equipment. Different equipment to be had at the platform come with Google Cloud’s Vertex AI, BigQuery, Healthcare API and Chronicle. The providing was once meant to assist organizations construct scalable and compliant AI-enabled tool for clinical imaging whilst making sure information safety.
